Jean Lachaine, Ph.D.
Affiliations: | 2000 | Université de Montréal, Montréal, Canada |
Area:
Health Care Management, OncologyGoogle:
"Jean Lachaine"Parents
Sign in to add mentor| Andre-Pierre Contandriopoulos | grad student | 2000 | Université de Montréal | |
| (Evaluation economique des antiemetiques utilises pour le controle des vomissements induits par chimiotherapie et evaluation des aspects economiques de la qualite de vie.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Poulin Y, Beauchemin C, Royer C, et al. (2020) Real-World Experience with Apremilast in the Treatment of Adults with Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization. Journal of Cutaneous Medicine and Surgery. 1203475420936652 |
| Lachaine J, Ben Amor L, Pringsheim T, et al. (2019) Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada. Journal of Child and Adolescent Psychopharmacology |
| Mathurin K, Beauchemin C, Lachaine J, et al. (2019) PIN33 COST-EFFECTIVENESS ANALYSIS OF EFINACONAZOLE FOR THE TREATMENT OF MILD TO MODERATE TOENAIL ONYCHOMYCOSIS IN CANADA Value in Health. 22: S199 |
| Stip E, Lachaine J. (2018) Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. Therapeutic Advances in Psychopharmacology. 8: 287-301 |
| Lambert-Obry V, Gouault-Laliberté A, Castonguay A, et al. (2018) Real-world patient- and caregiver-reported outcomes in advanced breast cancer. Current Oncology (Toronto, Ont.). 25: e282-e290 |
| Beauchemin C, Lapierre MÈ, Letarte N, et al. (2016) Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available. Pharmacoeconomics |
| Beauchemin C, Letarte N, Mathurin K, et al. (2016) A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. Journal of Medical Economics. 19: 619-29 |
| Lachance S, Bibeau J, Lachaine J. (2016) Burden of Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation on Health Care Resource Utilization in the Management of Acute Leukemia and Myelodysplastic Syndrome Blood. 128: 2372-2372 |
| Lambert-Obry V, Gouault-Laliberté A, Castonguay A, et al. (2016) Health Care Resource Utilization and Costs Associated with the Management of Non-Infectious Intermediate, Posterior and Panuveitis in Canada Value in Health. 19: A614 |
| Beauchemin C, Letarte N, Mathurin K, et al. (2016) A Global Economic Model to Assess the Cost Effectiveness of New Treatments for Advanced Breast Cancer in Canada Value in Health. 19: A151 |